David Knipe, Lynda Morrison, and Jeffrey Cohen are three of the principal scientists who have been involved in research over the past 15 years that has brought the HSV-2 ACAM-529 vaccine to a Phase I Clinical Trial.  Sanofi Pasteur is the company that has backed / sponsored the ACAM-529 vaccine, and Sanofi Pasteur will presumably be bringing the HSV-2 ACAM-529 vaccine to market if it succeeds in all phases of human clinical trials.

Dr. Knipe was kind enough to share the following information with me earlier today, which I pass along for those who may be interested in enrolling in the ACAM-529 vaccine clinical trial.

————————————————————–

Hi Bill,

Here are the links for the start of the HSV5-29 trial for your blog.

http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HSV11-8-13.aspx

http://hms.harvard.edu/news/targeting-hsv-11-8-13

If people want to write to me about the trial (I am not conducting it though), they can write to me at this address:  dknipe@hms.harvard.edu

Best,
David

—————————————————————

something completely differentDavid, I believe that I speak for millions of genital herpes sufferers worldwide when I say thank you for your dedication and perseverance over the past 15 years, which has brought ACAM-529 from a HSV-2 vaccine concept to the first human clinical trial of a HSV-2 viral vaccine that has real potential to be a game-changer.

You have my best wishes and hopes that the trials of the HSV-2 ACAM-529 vaccine represent a turning point in the development of a HSV-2 genital herpes vaccine that is both safe and effective.

– Bill H.



Pin It on Pinterest

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.